Clinical Trial Update: Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluate the safety and effectiveness of BMS-232632, a protease inhibitor, in HIV-infected patients who have received prior antiretroviral…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BMS-232632

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections | Phase 2 | Status: COMPLETED